Business Context and Reporting Period
Supernus Pharmaceuticals, Inc. filed a Form 8-K Current Report dated January 31, 2019. The filing discloses the entry into a material definitive agreement regarding the company's new corporate headquarters.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the terms of a new lease agreement.
Material Changes and Agreement Details
On January 31, 2019, the Company entered into a Lease Agreement with Advent Key West, LLC for approximately 136,016 square feet located at 9715 and 9717 Key West Avenue, Rockville, Maryland. Key terms include:
- Lease Term: Estimated commencement on or about February 1, 2019, continuing until April 30, 2034.
- Rental Rate: Initial fixed rent of $195,523 per month for the first 12 months, with automatic 2% annual increases thereafter.
- Security Deposit: $195,523.
- Additional Costs: The Company is responsible for all utility charges and its pro rata share of operating expenses and real estate taxes.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of risks beyond the obligations inherent in the lease agreement. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the exact commencement date of the lease, as the rental rate is contingent on possession being tendered on or about February 1, 2019.
- Review the full text of the Lease Agreement (Exhibit 10.1) for specific definitions of operating expenses and real estate tax pro rata shares.
- Confirm the impact of the $195,523 security deposit on the company's current cash position.